Two randomized , placebo-controlled trials were performed with 168 flavivirus-naive adults to demonstrate the safety and immunogenicity of a live attenuated tetravalent dengue vaccine ( TV003 ) , compared with those of a second tetravalent vaccine with an enhanced DENV-2 component ( TV005 ) , and to evaluate the benefit of a booster dose at 6 months .